Abbott Laboratories

Day range

$101.56 – $104.00

Open

$102.28

Prev close

$102.51

Volume

10.3M

Market cap

$177.38B

Shares out

1.73B

P/E

32.70

P/S

3.81

P/B

3.47

P/FCF

22.67

ROE

10.6%

ROA

5.0%

Debt/Equity

0.64

Div yield

2.40%

As of Oct 22, 2026

• Earnings and performanceOct 21, 2026

  On October 21, 2026, Abbott Laboratories announced its results of operations for the third quarter 2026. Furnished as Exhibit 99.1 ... is the news release issued by Abbott announcing those results.

• Material agreementsAug 20, 2026

  On August 20, 2026, rather than continuing to appeal or paying approximately $600 million (representing the Gill judgment plus accrued interest to date), Abbott entered into agreements to resolve the Gill lawsuit as well as NEC claims asserted on behalf of approximately 2,000 additional infants for an aggregate amount of approximately $670 million. These agreements are a compromise of disputed claims and not in any way an admission of liability.

• Shareholder meetingsApr 27, 2026

  Abbott held its Annual Meeting of Shareholders on April 24, 2026. The following is a summary of the matters voted on at that meeting. (1) The shareholders elected Abbott's entire Board of Directors. (2) The shareholders ratified the appointment of Ernst & Young LLP as Abbott's auditors. (3) The shareholders approved the compensation of Abbott's named executive officers. (4) The shareholders voted to approve the Abbott Laboratories 2026 Incentive Stock Program, with 95.82 percent of the votes cast voting 'For' the proposal. (5) The shareholders voted to approve the Abbott Laboratories 2026 Employee Stock Purchase Plan for Non-U.S. Employees, with 99.33 percent of the votes cast voting 'For' the proposal.

• Deal completionsMar 23, 2026

  On March 23, 2026, Abbott Laboratories, an Illinois corporation ("Abbott"), completed the acquisition of Exact Sciences Corporation, a Delaware corporation ("Exact Sciences"), pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the "Merger Agreement")... Merger Sub merged with and into Exact, with Exact surviving as a direct, wholly owned subsidiary of Abbott (the "Merger").

• Debt activityMar 9, 2026

  Abbott completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes, consisting of $1,000,000,000 aggregate principal amount of its Floating Rate Notes due 2029, $2,250,000,000 aggregate principal amount of its 3.700% Notes due 2029, $2,500,000,000 aggregate principal amount of its 4.000% Notes due 2031, $2,750,000,000 aggregate principal amount of its 4.300% Notes due 2033, $3,750,000,000 aggregate principal amount of its 4.650% Notes due 2036, $2,000,000,000 aggregate principal amount of its 4.750% Notes due 2038, $3,750,000,000 aggregate principal amount of its 5.500% Notes due 2056 and $2,000,000,000 aggregate principal amount of its 5.600% Notes due 2066.

• MDTMedtronic plc-1.22%
• ISRGIntuitive Surgical Inc.+1.90%
• DXCMDexCom, Inc.-0.48%
• ABBVABBVIE INC.+0.16%
• TMOThermo Fisher Scientific, Inc.-0.40%
• BSXBoston Scientific Corp.-0.70%
• JNJJohnson & Johnson-1.42%
• ITGRInteger Holdings Corporation-0.02%

Days to cover

1.5

Short interest

13.63M

Avg volume

9.34M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device
  negativeGlobeNewswire Inc.· Oct 22, 2026
• Abbott: 3 Key Takeaways for Long-Term Investors
  positiveThe Motley Fool· Oct 21, 2026
• Pre-Markets in Green on Strong Earnings Results
  positiveZacks Investment Research· Oct 21, 2026
• Pre-Markets Up on Cooling Metrics, Decent Q3 Reports
  positiveZacks Investment Research· Oct 21, 2026
• Abbott (ABT) Misses Q3 Earnings Estimates
  neutralZacks Investment Research· Oct 21, 2026